Therapeutic options for hepatocellular carcinoma (HCC) remain scarce and limited by resistance, underscoring the need for novel approaches. The lysine methyltransferase SMYD2 is overexpressed in several cancers and regulates oncogenic signaling through histone... ...

请注册登录后继续浏览